Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com -- Carl Zeiss Meditec AG (ETR:AFXG) shares traded higher on Tuesday after it reported second-quarter results in line with its April trading update, driven by stronger-than-expected performance in China refractive.
The healthcare company maintained its fiscal 2024/25 guidance, citing uncertainty around tariffs and currency risks as reasons for not offering further detail.
Quarterly revenue was €560 million, with EBITA at €78 million and earnings per share of €0.52.
Growth in refractive procedures in China offset a decline in Microsurgery sales, linked to the launch of the new Kinevo 900S microscope.
Gross margin slipped to 52.7% in the first half, from 53.3% a year earlier, due to a less favorable product mix.
This included more sales of lower-priced intraocular lenses in China and reduced sales of older-generation machines following new product introductions.
The company maintained guidance for “moderate revenue growth” and “stable to slightly higher EBITA,” noting that macroeconomic and geopolitical uncertainty, including possible U.S. tariffs and currency volatility, prevents a more precise forecast.
RBC Capital Markets said the results align with expectations set in April and may reassure investors.
Analysts anticipate that focus will shift to risks around tariffs and China’s market dynamics during upcoming discussions.
Company-compiled consensus as of March 2025 projects revenue of €2.19 billion and EBITA of €275.2 million for FY2024/25, up from €246 million last year. RBC noted that expectations may have edged higher since April’s update.
Separately, the company confirmed CEO Markus Weber will step down May 31. He will be succeeded by Maximilian Foerst, head of ZEISS Greater China since 2009.